DNA Polymerase Market Size To Reach $136.5 Million By 2030

DNA Polymerase Market Growth & Trends 

The global DNA polymerase market size is expected to reach USD 136.5 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 1.30% from 2023 to 2030. DNA polymerase are essential enzymes involved in the replication and repair of DNA in living organisms. These polymerases market has experienced significant growth in recent years due to the increasing demand for DNA polymerases in various applications, such as molecular diagnostics, genetic engineering, and drug development. Moreover, the increasing use of such polymerases in various industries, such as pharmaceuticals, agriculture, and forensics, has further fueled the expansion of this market. 

In addition, rising prevalence of genetic disorders and cancers is another factor is driving the growth of the market. According to the Genetic and Rare Disease (GARD) Information Centre reports there are more than 7,000 rare diseases. In the U.S. alone, it is estimated that between 25 million and 30 million people are living with a rare disease, and this number continues to rise. Additionally, at least 200,000 people are known survivors of genetic disorders, while over 30,000 babies and children are diagnosed annually with genetic disorders in the UK, resulting in more than 2.4 million survivors of various genetic conditions. This trend is expected to continue over the forecast period, leading to a growing demand for DNA polymerase and related products.

The COVID-19 pandemic has led to an increased demand for diagnostics and therapeutic development, resulting in a surge in the market. To better understand the virus and develop effective testing strategies, researchers and healthcare professionals have relied on DNA polymerases for various molecular diagnostic techniques, such as PCR and RT-PCR. This increased demand has resulted in a significant expansion of the market. The urgency to combat COVID-19 has propelled scientific innovation and collaboration efforts to develop new diagnostic tools and therapies. For instance, Ginkgo Bioworks, a biotechnology company, has launched Concentric by Ginkgo, a large-scale COVID-19 testing service that depends on DNA polymerase-based techniques like PCR. This initiative showcases the role of DNA polymerases in innovative diagnostic solutions. 

The development of novel DNA polymerase with enhanced properties, such as high fidelity, processivity, and resistance to inhibitors, has expanded their range of applications. These advancements have allowed researchers to conduct more complex experiments and explore previously inaccessible areas of the genome. As the demand for efficient and accurate DNA polymerases increases, innovations in this area are expected to boost the market further. 

Furthermore, the growing investment in personalized medicine research and the rising awareness of its benefits are expected to drive the market in the coming years. For instance, in December 2020, Tempus, a precision medicine technology company, secured USD 200 million in Series G-2 funding, leading to a substantial valuation of USD 8.1 billion. The company plans to use the additional funding to expand its operations and focus on a range of diseases, including infectious diseases, depression, and cardiology. Personalized medicine is an emerging field that aims to provide tailored treatment options based on an individual's genetic makeup. DNA polymerase play a crucial role in sequencing, which is an essential component of personalized medicine.

 Request a free sample copy or view report summary: DNA Polymerase Market Report

DNA Polymerase Market Report Highlights

• By type, the Taq polymerase segment dominated the market with a share of 53.99% in 2022. Taq polymerases are a type of DNA polymerases that is commonly used in the PCR technique. As research in genetics and molecular biology continues to expand, the demand for PCR is expected to increase, driving the growth of this segment

• The polymerase chain reaction segment accounted for the largest share of 74.85% in the application segment in 2022, due to the widespread use of the DNA amplification technique for diagnostic and research purposes

• The hospitals and diagnostic centers segment accounted for the largest market share of 41.65% in 2022 due to the increasing prevalence of genetic disorders and infectious diseases like COVID-19 which led to a surge in the adoption of polymerase-based testing options

• North America has established a strong regional position in the market with 47.25% share in 2022, which can be attributed to the high demand for biotechnology techniques. The region is home to numerous prominent biotech and pharmaceutical companies that invest heavily in research and development of new drugs and therapies. 

DNA Polymerase Market Segmentation

Grand View Research has segmented the global DNA polymerase market based on type, application, end-use, and region:

DNA Polymerase Type Outlook (Revenue, USD Million, 2018 - 2030)

• Taq Polymerase

• Pfu Polymerase

• Proprietary Enzyme Blends

• Others

DNA Polymerase Application Outlook (Revenue, USD Million, 2018 - 2030)

• Polymerase Chain Reaction

• DNA Sequencing

• DNA Cloning

• Others

DNA Polymerase End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical and Biotechnology Companies

• Academic and Research Institutes

• Hospitals & Diagnostic Centers

• Others

DNA Polymerase Regional Outlook (Revenue, USD Million, 2018 - 2030) 

• North America

• U.S.

• Canada

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• South Korea

• Australia

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait 

List of Key Players of DNA Polymerase Market 

• Thermo Fisher Scientific, Inc.

• Agilent Technologies

• Merck KGaA

• Danaher

• QIAGEN

• Hoffmann-La Roche Ltd.

• Bio-Rad Laboratories, Inc.

• Takara Bio, Inc.

• Promega Corporation

• New England Biolabs